Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study investigates whether the prophylactic use of moxifloxacin during high-dose
chemotherapy followed by autologous stem cell transplantation reduces the incidence of
clinically significant bacteremia.
Further investigations include time to occurrence of fever, duration of fever, overall
survival and antibiotic sensitivity of blood isolates.
Phase:
Phase 3
Details
Lead Sponsor:
University of Cologne
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination